

Pembrolizumab KEYNOTE-522

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-522

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence

Experimental Arm: Pembrolizumab + ChT (paclitaxel + carboplatin)

Control Arm: Placebo plus ChT (paclitaxel + carboplatin)



